---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-024549"
form_type: "8-K"
ticker: null
cik: "0001403708"
company_name: "Evoke Pharma Inc"
filed_at: "2023-05-26T23:59:59+00:00"
generated_at: "2026-06-14T12:43:42.522373+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Evoke Pharma receives Nasdaq deficiency notice for stockholders' equity below $2.5M

## Summary
- Stockholders' equity of $2.1M as of March 31, 2023 misses Nasdaq minimum $2.5M requirement.
- Company must submit a compliance plan to Nasdaq by July 10, 2023.
- If plan accepted, Nasdaq may grant up to 180-day extension to regain compliance.
- Failure to regain compliance could lead to delisting from Nasdaq Capital Market.

## SEC filing metadata
- accession: 0000950170-23-024549
- form_type: 8-K
- cik: 0001403708
- company_name: Evoke Pharma Inc
- filed_at: 2023-05-26T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1403708/000095017023024549/0000950170-23-024549-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1403708/000095017023024549/evok-20230524.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-024549
- JSON: https://secwatch.observer/filing/0000950170-23-024549.json
- Plain text: https://secwatch.observer/filing/0000950170-23-024549.txt

## Key facts
- Listing & Compliance Notices
  Evoke Pharma Inc received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).
  - Exchange: nasdaq
  - Notice: deficiency notice
  - Deficiency: stockholders equity
  - Rules: 5550(b)(1)
  source text: May 24, 2023, Evoke Pharma, Inc. (the “Company”) received written notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, based on the Company’s stockholders’ equity of $2.1 million as of March 31, 2023, as reported in the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2023, it is not in compliance with the minimum stockholders’ equity requirement for continued listing on the Nasdaq Capital Market under Nasdaq Listing Rule 5550(b)(1), which requires listed companies to maintain stockholders’ equity of at least $2.5 m
  evidence_url: https://www.sec.gov/Archives/edgar/data/1403708/000095017023024549/0000950170-23-024549-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.